A lot has been stated about the Maintenance of Certification (MOC) implemented by the American Board of Internal Medicine (ABIM,) and many physicians, regardless of specialty, have been opposed to the MOC as it adds cost, burden, and takes away from patient care. This led Dr. Aaron Goodman from UCSD to start a petition to end the MOC, which gathered unwavering support with over 10,000 signatures in 2 weeks. In response, Dr. Richard Baron, the president and CEO of ABIM, has agreed to come on the show to address the concerns raised by physicians and to answer questions that have flooded all social media channels since the petition started.
What is the history of certification, recertification, and MOC? What is the “Grandfather” rule? What about data? COI? Cost? Burnout? Does the MOC really lead to better patient care? Why not stick to state-regulated CME courses? These issues are top-of-mind for a large number of physicians who are certified by the ABIM.
You will not want to miss this heated, yet respectful and civil, discussion.
In the podcast, there is a mention of COIs. The ABIM has provided links to their COI.
Dr. Baron’s specific COI are also listed: https://www.abim.org/about/leadership/#baron
The ABIM Board of Directors page lists all of their COIs as well: https://www.abim.org/about/boards-and-committees/governance/board-of-directors/
Here is the page for all the Specialty Boards: https://www.abim.org/about/boards-and-committees/
View the petition: https://www.change.org/p/eliminate-abims-moc-requirement
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
